M MagellanLONGEVITY

NMDA / Glutamate

Ketamine

NMDA antagonist; refractory and neuropathic pain.

Listen: research reviews

Short AI-narrated discussions of the evidence on Ketamine. Press play or read the transcript.

Review & discussion 1
Read transcript

Speaker 1...and the connection between pain and aging is really quite striking. We know that chronic pain itself seems to accelerate biological aging.

Speaker 2Exactly. A study in *GeroScience* from 2025, for example, found that painful diabetic neuropathy was linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy. So, treating pain can certainly be a health imperative.

Speaker 1And one molecule sometimes used for refractory or neuropathic pain is ketamine, an NMDA antagonist. It can be very effective in appropriate, supervised settings.

Speaker 2Absolutely. However, when we look at its long-term impact on biological aging or all-cause mortality, the picture gets murkier. While it can alleviate pain, which theoretically should be beneficial for aging, direct evidence linking ketamine to slowing or reversing biological aging is largely unestablished.

Speaker 1And we also have to consider potential long-term risks. High-dose or prolonged ketamine use can carry risks like cognitive issues, bladder dysfunction, or cardiovascular strain. These aren't minor, and they could indirectly impact overall health and longevity.

Speaker 2Precisely. The evidence doesn't yet show that ketamine *improves* all-cause mortality or biological aging markers. In fact, some of its potential harms might work against those very goals.

Speaker 1So, it’s a careful balance. For some, the relief from chronic, debilitating pain is life-changing, and the benefits might outweigh these uncertainties. But it's crucial to acknowledge what the science *doesn't* yet confirm regarding direct longevity benefits or harms beyond its pain-relieving effects.